Asthma remission and its predictors in severe asthma: real-world study from the Korean severe asthma registry

Sep 30, 2026

Uploaded by Stanford

Evaluate asthma remission achievement and predictors among Korean patients with severe asthma using nationwide prospective real-world cohort data from KoSAR. Analyze 405 participants completing 12-month follow-up and classify remission at 12 and 24 months as complete clinical remission, clinical remission, partial remission, or no remission. Use ordinal logistic regression to identify baseline predictors of higher remission, while examining clinical and treatment-related features associated with remission status.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages11

Reading Time28 min

AccessFree to download

Abstract

Methods

Results

Conclusions

Introduction

Background and rationale

Methods

Patients and study design

Lee et al. Respiratory Research (2026) 27:8 [https://doi.org/10.1186/s12931-025-03451-y](https://doi.org/10.1186/s12931-025-03451-y) Respiratory Research RESEARCH Open Access Asthma remission and its predictors in severe asthma: real-world study from the Korean severe asthma registry Seung-Eun Lee 1, Byung-Keun Kim2, Noeul Kang3, Youngsoo Lee4, Yoon-Seok Chang5, Da Woon Sim6, Hyo-In Rhyou7, Jae-Woo Jung8, Jae-Woo Kwon9, Sujeong Kim 10, Taehoon Lee 11, Ga-Young Ban 12, Kyoung-Hee Sohn 13, Sang-Hoon Kim 14, An-Soo Jang 15, Sung-Yoon Kang 16, Min Suk Yang 17, So Ri Kim 18, Hyun Jung Jin 19, Young-Hee Nam20, Ji Hyun Oh21, Min-Hye Kim22, Jin An23, Hwa Young Lee24, Han-Ki Park25, Eun-Jung Jo26, Ji-Ho Lee27, Heung-Woo Park28, Joo-Hee Kim29, Woo-Jung Song30, Sang-Heon Kim31 and So-Young Park8,32,33* Abstract Background Remission has emerged as a therapeutic goal in asthma, but most studies in severe asthma have focused on biologic-treated patients in controlled settings. Real-world data from Asian populations are scarce. We aimed to evaluate the achievement and predictors of asthma remission in Korean patients with severe asthma using a nationwide prospective cohort. Methods We analyzed 405 patients with severe asthma from the Korean Severe Asthma Registry (KoSAR) who completed 12-month follow-up. Remission was classified at 12 and 24 months as complete clinical remission (CCR; ACT ≥ 20, no exacerbations, no oral corticosteroid [OCS] use, and FEV₁ ≥80% or improvement ≥ 100 mL), clinical remission (CR; first three criteria), partial remission (PR; ≥1 criterion), and no remission (NR; none) . Ordinal logistic regression identified baseline predictors of higher remission. Results At 12 months, CCR, CR, PR, and NR were achieved in 5. 9%, 18. 3%, 67 . 9%, and 7 . 9% of participants. Among those with 24-month follow-up (n = 139), remission status was largely stable. Higher baseline ACT score (OR: 1. 19, 95% CI 1.12–1. 27) predicted remission, while maintenance OCS use (OR: 0 . 11, 95% CI 0.05–0. 25) and chronic cough (OR: 0 . 39, 95% CI 0 .17–0. 89) were negatively associated. Remission groups had better baseline lung function, fewer exacerbations, and low WBC counts. Baseline biologic use was more common in CCR, CR groups, whereas NR patients more frequently received methylxanthines, macrolides, and OCS. Conclusions Clinical predictors, including asthma control, OCS use, and chronic cough may help guide remissionfocused strategies in the treatment of severe asthma. Keywords Asthma, Severe asthma, Remission, Biologics, Chronic cough *Correspondence: So-Young Park [raina82@cau.ac.kr](raina82@cau.ac.kr); [raina821563@gmail.com](raina821563@gmail.com) Full list of author information is available at the end of the article © The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. Lee et al. Respiratory Research (2026) 27:8 Introduction Asthma is a chronic inflammatory airway disease with a variable clinical course [1]. Patients with severe asthma continually experience uncontrolled symptoms, frequent exacerbations, and impaired quality of life despite high-dose inhaled cortico

FAQs

How is asthma remission defined in this severe asthma study?

Remission at 12 and 24 months is classified as complete clinical remission, clinical remission, partial remission, or no remission based on symptom control, exacerbations, oral corticosteroid (OCS) use, and lung function criteria.

What predictors were associated with higher remission?

A higher baseline ACT score predicted remission, while maintenance OCS use and chronic cough showed negative associations with remission outcomes.

Were remission statuses stable over time?

Among participants with 24-month follow-up, remission status was largely stable, indicating persistence of remission patterns across the longer observation period.

Sep 30, 2026

Uploaded by Stanford